Ipsen to Present Phase II Data on Corabotase at SCALE Symposium 2026
Ipsen announced on Thursday the presentation of Phase II data for corabotase, an experimental molecule classified as the first of a new therapeutic class called recombinant neuro-inhibitor (RNI). The results, which concern the treatment of glabellar lines, will be presented at the SCALE symposium on May 16, 2026.
Corabotase: Design and Recognition of a New Class
Corabotase (IPN10200) was developed using advanced protein engineering techniques and Ipsen's proprietary manufacturing platform. The molecule combines an active catalytic domain with an enhanced affinity binding domain, each element deliberately optimized to increase receptor affinity, improve absorption, and enhance resistance to degradation.
The recognition of corabotase as the first molecule of a new therapeutic class by the WHO and USAN reflects its scientific novelty and Ipsen's historic positioning in neuroscience, according to Christelle Huguet, Executive Vice President and Director of R&D at the group.
LANTIC Trial: Ongoing Multi-Indication Program
The LANTIC trial (n = 727) assesses the safety and efficacy of corabotase in three aesthetic indications concerning moderate to severe upper facial lines: glabellar lines, forehead lines, and lateral canthal lines. The study is structured in three stages, with Phase II comparing corabotase to a placebo and Dysport.
In September 2025, Ipsen reported positive Phase II data from the first stage, confirming a differentiated clinical profile for corabotase in glabellar lines, with a rapid onset of action and a clinically sustained duration of effect. Proof of concept data for the other two aesthetic indications are expected later in 2026. Beyond LANTIC, an extensive Phase II and Phase III clinical program is advancing corabotase in multiple aesthetic and therapeutic indications.
